Importance: Widespread distribution of rapid antigen tests is integral to the US strategy to address COVID-19; however, it is estimated that few rapid antigen test results are reported to local departments of health.

Objective: To characterize how often individuals in 6 communities throughout the United States used a digital assistant to log rapid antigen test results and report them to their local departments of health.

Design, Setting, And Participants: This prospective cohort study is based on anonymously collected data from the beneficiaries of the Say Yes! Covid Test program, which distributed more than 3 000 000 rapid antigen tests at no cost to residents of 6 communities (Louisville, Kentucky; Indianapolis, Indiana; Fulton County, Georgia; O'ahu, Hawaii; Ann Arbor and Ypsilanti, Michigan; and Chattanooga, Tennessee) between April and October 2021. A descriptive evaluation of beneficiary use of a digital assistant for logging and reporting their rapid antigen test results was performed.

Interventions: Widespread community distribution of rapid antigen tests.

Main Outcomes And Measures: Number and proportion of tests logged and reported to the local department of health through the digital assistant.

Results: A total of 313 000 test kits were distributed, including 178 785 test kits that were ordered using the digital assistant. Among all distributed kits, 14 398 households (4.6%) used the digital assistant, but beneficiaries reported three-quarters of their rapid antigen test results to their state public health departments (30 965 tests reported of 41 465 total test results [75.0%]). The reporting behavior varied by community and was significantly higher among communities that were incentivized for reporting test results vs those that were not incentivized or partially incentivized (90.5% [95% CI, 89.9%-91.2%] vs 70.5%; [95% CI, 70.0%-71.0%]). In all communities, positive tests were less frequently reported than negative tests (60.4% [95% CI, 58.1%-62.8%] vs 75.5% [95% CI, 75.1%-76.0%]).

Conclusions And Relevance: These results suggest that application-based reporting with incentives may be associated with increased reporting of rapid tests for COVID-19. However, increasing the adoption of the digital assistant may be a critical first step.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419013PMC
http://dx.doi.org/10.1001/jamanetworkopen.2022.28885DOI Listing

Publication Analysis

Top Keywords

rapid antigen
32
digital assistant
24
antigen test
16
rapid
9
test
9
antigen
8
health departments
8
distribution rapid
8
antigen tests
8
reported local
8

Similar Publications

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

PCM Consulting, Pathways Connectivity Maps Inc., Mountain View, CA, USA.

Background: High-throughput assays have attracted significant attention in Alzheimer's Disease (AD) research, especially for enabling rapid diagnostics screening for factors at the molecular level contributing to the disease recurrence. With advances in laboratory automation, there is a growing need for quality pre-clinical data. Assays such as Microarrays, Proteomics, or AI are all dependent on high-quality input data that serve as a starting point.

View Article and Find Full Text PDF

Introduction: Prostate cancer is incidentally diagnosed in 6%-11% of benign prostatic hyperplasia surgeries.

Case Presentation: A 79-year-old man was diagnosed with benign prostatic hyperplasia. The prostate volume was 54.

View Article and Find Full Text PDF

Objective: The study compared the mö-screen Corona Antigen Test (Qiagen, Germany) with RT-PCR in suspected COVID-19 patients.

Materials And Methods: Two hundred combined oro-nasopharyngeal swabs were collected from patients with suspected COVID-19 to evaluate the analytical performance of the mö-screen Corona Antigen Test compared to qualitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) in symptomatic patients.

Results: The mö-screen Corona Antigen Test showed an overall agreement with a sensitivity of 100%, a specificity of 100%, a positive predictive value (PPV) of 100%, and a negative predictive value (NPV) of 100%.

View Article and Find Full Text PDF

Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies.

Theranostics

January 2025

Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, China.

T cell receptor-engineered T (TCR-T) cell therapies are at the forefront of cancer immunotherapy, offering a transformative approach that significantly enhances the ability of T cells to recognize and eliminate cancer cells. This innovative method involves genetically modifying TCRs to increase their affinity for tumor-specific antigens. While these enhancements improve the ability of T cells to recognize and bind to antigens on cancer cells, rigorous assessment of specificity remains crucial to ensure safety and targeted responses.

View Article and Find Full Text PDF

Pleural tuberculosis (pTB) is a diagnostic challenge because of its non-specific clinical features, lack of accurate diagnostic tools and paucibacillary nature of the disease. We, here describe the development of a novel magnetic nanoparticle antibody-conjugate and aptamer-based assay (MNp-Ab-Ap assay) targeting 4 different (. ) antigens (GlcB, MPT51, MPT64 and CFP-10) for pTB diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!